MAVENIR/MOBILEDGEX
22.6.2021 15:02:08 CEST | Business Wire | Press release
Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner.
“We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom.
A service-based, cloud-native UPF is at the core of the reference design. Since the introduction of mobile packet data in 3G, all data traffic, irrespective of source, destination, and requesting application, has been tunneled back to a limited number of fixed (packet gateway) anchor points inside the mobile networks. This is increasingly inefficient, non-performant, and prone to bottlenecks. 5G Core standards enable dynamic placement of the anchor point (the UPF) based on the application and network’s needs. The combination of Mavenir’s widely deployed 4G/5G cloud-native Converged Packet Core solution, coupled with the MobiledgeX Edge-Cloud platform enables the UPF to be placed on different clouds from different vendors with different ownership. Service provider control, security, and privacy are maintained by a customer’s owning operator at all times, even when roaming. This architecture helps optimal placement of the application’s backend servers, enabling a superior user experience and increased network efficiency, by significantly reducing the distance the data needs to travel before it is processed.
Validated Reference Design
For this trial validation, the Mavenir 5G Core is running in Deutsche Telekom’s network. Two network and vendor-independent cloudlets, located in Germany, have been deployed as valid UPF placements in the 5G Core routing. For instance, a video application is started on a 5G phone connected to Deutsche Telekom’s 5G network in Berlin. The request is sent to the 5G Core that selects UPF placement in the Berlin cloudlet. Tunneling is established. The video request is passed to the local edge-placed video cache and delivery commences. The identical request is made in Hanover. The traffic is then established to the Hanover cloudlet and local fulfillment occurs there. The MobiledgeX Edge Cloud 3.0 platform dynamically controls the secure placement, lifecycle management, and video traffic routing of the edge-based UPF and the video application.
“This is a successful milestone for cloud-native 5G Core traffic routing, giving Deutsche Telekom the freedom to deliver a point of interconnect/local breakouts anywhere in the world, on any cloud,” says Bejoy Pankajakshan, Chief Strategy Officer, Mavenir. “Cloud-native design of 5G network functions integrated with orchestration tools makes it possible to achieve a new level of flexibility in network function placement. Automation, agility, and flexibility are at the heart of this project.”
“The MobiledgeX Edge-Cloud platform enables our operator customers to dynamically manage and allocate UPF functionality across their own cloud infrastructure independent of vendor, in roaming partners mobile networks, in private 4G/5G networks, and in public clouds, all through one pane of glass and in one trusted and secure operation,” says Sunay Tripathi, Chief Technology Officer & EVP of Engineering & Product, MobiledgeX. “Cloud-native UPF operation transforms traffic patterns in mobile operator networks, making the telecom operator the largest customer of their own edge cloud offering which is necessary to be a true cloud leader. We are very excited that Deutsche Telekom has taken the initiative to lead.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About MobiledgeX
MobiledgeX is working with global mobile operators to deliver full control over multi-cloud edge deployments. The company’s MobiledgeX Edge-Cloud platform provides a common interface for managing application workloads anywhere, abstracted from underlying infrastructure, to maintain control over data, privacy and security. It also provides device native SDK and matching engines for operator and third-party application developers to maximize performance and efficiency for cloud-native applications at the edge. MobiledgeX Edge-Cloud is proven in market today via trials, proofs of concepts and deployments that involve more than 20 global operators and a range of next-gen app developers.
MobiledgeX is an edge computing company founded by Deutsche Telekom AG and headquartered in San Jose, California. https://mobiledgex.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom